CoChat

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Purpose of review Summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2022 scientific session of the American Heart Association (AHA). Recent findings The PROMINENT trial compared pemafibrate to a placebo in patients with type 2 diabetes mellitus (DM) and mild-to-moderate hypertriglyceridemia and high-density lipoprotein cholesterol (HDL-C)<40 mg/dL who were already on guideline-directed statin therapy. The RESPECT-EPA trial compared purified eicosapentaenoic acid (EPA) and statin therapy to statin therapy alone for secondary prevention of atherosclerotic CV disease (ASCVD). SPORT compared the efficacy of low-dose statin therapy with a placebo and six commonly used dietary supplements on lipid and inflammatory markers. Data from long-term follow-up of the FOURIER-OLE study was presented to evaluate the efficacy of very low low-density lipoprotein cholesterol (LDL-C) levels with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Patient-level meta-analyses evaluated the association of statin therapy with new-onset DM and worse glycemic control. PROMPT-LIPID evaluated if automated electronic alerts to physicians with guideline-based recommendations improved the management of hyperlipidemia in patients at very high risk. NOTIFY-1 trial evaluated if notifying physicians and patients about coronary artery calcium (CAC) scores in non-ECG gated computed tomography scans led to increased prescription of statin therapy for…

Overview

Integrity signals

Registry

Crossref · 10.1007/s11883-022-01079-7

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 34 references

Cited by

See all 9

Metadata

Authors
Gupta, K., Hirsch, J. R., Kalsi, J., Patel, V., Gad, M. M., & Virani, S. S.
Affiliations
  • Henry Ford Health (US)
  • Baylor College of Medicine (US)
  • Henry Ford Hospital (US)
  • Michael E. DeBakey VA Medical Center (US)
Corresponding author
Virani, Salim S.
Venue
Current Atherosclerosis Reports
Published
2023-01
Volume
25
Issue
1
Pages
31-41
ISSN
  • 1523-3804 (ISSN-L)
  • 1534-6242
OpenAlex
W4313500743
Cited by
9
References
34
Citations by year
2025: 1 · 2024: 4 · 2023: 4
FWCI
0.58
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Atherosclerosis Reports (publishedVersion)
  • PubMed (publishedVersion)
  • eCommons - AKU (Aga Khan University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
cardiovascular disease prevention, type 2 diabetes, hypertriglyceridemia, pemafibrate, eicosapentaenoic acid, statin therapy, secondary prevention, atherosclerotic cardiovascular disease, dietary supplements, PCSK9 inhibitors, very low LDL-C, statin-induced diabetes, hyperlipidemia management, coronary artery calcium, hypertension, hydrochlorothiazide, chlorthalidone, antihypertensive drugs, angiotensin receptor blockers, lipid-lowering therapy
MeSH terms
Proprotein Convertase 9, American Heart Association, Anticholesteremic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Hypertension, Cholesterol, HDL, United States, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions. https://app.cochat.ai/papers/10.1007/s11883-022-01079-7
The paper
Gupta, K., Hirsch, J. R., Kalsi, J., Patel, V., Gad, M. M., & Virani, S. S. (2023). Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-022-01079-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.